Rocbrutinib clinical trials
Also written LP-168 and NWP-775.
How each study uses rocbrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rocbrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 1
Guangzhou Lupeng Pharmaceutical Company LTD. (12) · Newave Pharmaceutical Inc (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Zulfa Omer (1)
Often tested with
Tested in the same studies.
R-GemOx Regimen (1) · Lacutoclax (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test rocbrutinib.
- Mar 2027A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaPhase 1 · Guangzhou Lupeng Pharmaceutical Company LTD.
- Jun 2027Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaPhase 1 · Guangzhou Lupeng Pharmaceutical Company LTD.
Studies
Open first, then newest update. How each study uses rocbrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingPhase 3Newave Pharmaceutical IncNCT07342478Written as Rocbrutinib
- A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaRecruitingPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT04993690Written as LP-168 tablet
- A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT07570017Written as Rocbrutinib
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07776743Written as Rocbrutinib
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingPhase 1/2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07609862Written as Lacutoclax+Rocbrutinib
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib TabletRecruitingPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT07374224Written as Rocbrutinib tablets
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingPhase 1Newave Pharmaceutical IncNCT04775745Written as LP-168
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Rocbrutinib
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07189065Written as Rocbrutinib
- LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisRecruitingPhase 2Zulfa OmerNCT06978088Written as LP-168
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.Not yet recruitingPhase 1/2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06864507Written as HS-10561
- Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT06251180Written as Rocbrutinib
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT05716087Written as Rocbrutinib
- The Mass Balance Study of LP-168 in Healthy SubjectsCompletedPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT06126861Written as [14C]LP-168
- A Food Effect Study of LP-168 Tablets in Healthy SubjectsCompletedPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT05917964Written as LP-168 tablet
- A Study of LP-168 in Healthy VolunteersCompletedPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT05432713Written as LP-168 tablet
Codes
What other systems call rocbrutinib · ClinicalTrials.gg INT017056
- UNII (FDA) KD68L3GRW2ROCBRUTINIBConfirmed FDA, Wikidata
- Wikidata Q140641595rocbrutinibConfirmed FDA, Wikidata
- NCI Thesaurus C203033RocbrutinibOne source FDA
- DrugBank DB19445One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KD68L3GRW2 | ROCBRUTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140641595 | rocbrutinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C203033 | Rocbrutinib | One source FDA |
| DrugBank | DB19445 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.